Biopharmaceutical News and Research

RSS

Aeterna Zentaris raises US$5.1 million from institutional investors

AEterna Zentaris Inc., (the "Company") a global biopharmaceutical company focused on endocrine therapy and oncology, announced today that it has completed its previously announced registered direct offering of US$5.5 million of units comprised of common shares and common share purchase warrants to certain institutional investors.

24 Oct 2009

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Medgenics is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Sinovac Biotech to distribute PANFLU.1 vaccine in Mexico

Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has received a Certificate of Approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico. The certificate is valid through October 13, 2014.

23 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

PAREXEL to present key trends in late phase development and Comparative Effectiveness Research

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will address key trends in late phase development and Comparative Effectiveness Research at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress, to be held from October 24 - 27, 2009 in Paris, France.

From Parexel 22 Oct 2009

Sartorius reports financial results for the third quarter of 2009

Today Sartorius, a leading international process and laboratory technology provider, reported its nine-month results for 2009. Third-quarter business of both Group divisions showed a highly divergent pattern of development, similar to that in the previous quarters.

From Sartorius 22 Oct 2009

Unilife Medical Solutions to market its products at pharmaceutical industry event

Unilife Medical Solutions Limited today announced it will be exhibiting at two upcoming pharmaceutical trade shows and conferences.

22 Oct 2009

Complex issue of CER in biopharmaceutical development explored

In a new report released today, John Doyle, Vice President and Practice Leader for Quintiles Consulting, and an expert on pharmaceutical market access, explores the complex issue of comparative effectiveness research (CER) and its strategic importance in successful and efficient biopharmaceutical development.

22 Oct 2009

SNAP Diagnostics joins SAFE-BioPharma Association

SNAP Diagnostics, a Chicago-based leader in the development of technology for the detection of sleep apnea and the analysis of snoring patterns, has joined SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries. SNAP Diagnostics is the first dedicated device and diagnostics company to join SAFE-BioPharma.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

NIH awards $3.7 million to Johns Hopkins scientists for research on stem cells developed from ALS patients' skin

Johns Hopkins scientists have been awarded a $3.7 million grant from the National Institutes of Health (NIH) to learn more about the nerve and muscle-wasting disease amyotrophic lateral sclerosis (ALS) using stem cells developed from ALS patients' skin. The award, given over a two-year span, will be shared with three other laboratories, including one at Harvard University and two at Columbia University.

22 Oct 2009

Laureate Pharma signs development and manufacturing agreement to develop fusion protein products

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with an undisclosed client.

22 Oct 2009

Shire to file a Biologics License Application for REPLAGAL with the FDA

Shire plc, the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease, by the end of the year.

21 Oct 2009

Logical Therapeutics to present its clinical study results on LT-NS001

Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

21 Oct 2009

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

20 Oct 2009

New technique to treat metabolic disorders in babies while still in the womb

Researchers say a new development in cord blood transplants for inherited metabolic disorders may be curative for some babies who are treated while still in the womb.

20 Oct 2009

Biopharmaceutical News and Research

Aeterna Zentaris raises US$5.1 million from institutional investors

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Shire announces new pharmacokinetic data of ADHD medication

Sinovac Biotech to distribute PANFLU.1 vaccine in Mexico

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

PAREXEL to present key trends in late phase development and Comparative Effectiveness Research

Sartorius reports financial results for the third quarter of 2009

Unilife Medical Solutions to market its products at pharmaceutical industry event

Complex issue of CER in biopharmaceutical development explored

SNAP Diagnostics joins SAFE-BioPharma Association

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

NIH awards $3.7 million to Johns Hopkins scientists for research on stem cells developed from ALS patients' skin

Laureate Pharma signs development and manufacturing agreement to develop fusion protein products

Shire to file a Biologics License Application for REPLAGAL with the FDA

Logical Therapeutics to present its clinical study results on LT-NS001

Targacept presents data from Phase 2b clinical trial of TC-5214

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

New technique to treat metabolic disorders in babies while still in the womb

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News